In the News – ORGANOPlus

ORGANOPlus Participates in 2026 SMART AGRITECH: GLOBAL NETWORKING DAY

Stanley 2026.09.30 No Comments

ORGANOPlus joined the 2026 SMART AGRITECH: GLOBAL NETWORKING DAY to engage with investors and global partners on commercialization and international expansion. The event also highlighted the company’s growing global footprint,…

AFPRO 2026: ORGANOPlus to Unveil VILLIORGAN™ for AI-Driven Livestock ESG Innovation

Stanley 2026.07.13 No Comments

ORGANOPlus will participate in AFPRO 2026, held from July 15 to 17 at COEX in Seoul. The company will showcase VILLIORGAN™, an AI-powered animal biomimetic platform designed to evaluate gut…

CPHI South East Asia 2026: ORGANOPlus Showcases Proprietary Probiotic Strain OP820

Stanley 2026.07.13 No Comments

ORGANOPlus presented Bifidobacterium adolescentis OP820 and its human gut-mimicking platform, VILLIORGAN™, at CPHI South East Asia 2026 in Bangkok. The company introduced its capabilities in probiotic strain discovery, functional validation,…

ORGANOPlus Exhibits Human Validation Platform at BIO KOREA 2026

Stanley 2026.04.29 No Comments

ORGANOPlus exhibited its human-relevant validation platform at BIO KOREA 2026.The company highlighted CANORGAN™ for tumor microenvironment-based immuno-oncology validation and VILLIORGAN™ for microbiome-related mechanism discovery.The platform supports preclinical decision-making with more…

AACR 2026 Highlights the Shift Toward Human-Relevant Platforms in Cancer Research

Stanley 2026.04.27 No Comments

At AACR 2026, global attention focused on emerging technologies designed to reduce reliance on animal testing and improve the predictability of cancer research. Among them, ORGANOPlus presented its organ-on-chip platform,…

AACR 2026: ORGANOPlus Presents Preclinical Data on Microbiome-Derived Anticancer Candidate ‘OP820’

Stanley 2026.04.23 No Comments

ORGANOPlus presented preclinical data on its microbiome-derived anticancer candidate ‘OP820’ at AACR 2026 in San Diego. The study demonstrated the anti-inflammatory and anticancer effects of Bifidobacterium adolescentis OP820, identified through…

ORGANOPlus Participates in Inha University Hospital Open Lab “Connect Day” Networking Forum

Stanley 2026.04.17 No Comments

ORGANOPlus was selected as a participating company in the Inha University Hospital Open Lab program and joined the 2026 “Connect Day” networking forum.The event brought together 26 innovative biotech companies…

ORGANOPlus Showcases Oncology Validation Platform at BIO-Europe Spring 2026

Stanley 2026.03.31 No Comments

ORGANOPlus presented its tumor microenvironment–based organ-on-a-chip platform at BIO-Europe Spring 2026, enabling human-relevant validation of oncology candidates.Partnering discussions confirmed growing demand for predictive, human-derived evaluation systems beyond traditional models.

AACR 2026 Selects ORGANOPlus’ Microbiome Oncology Candidate OP820 for Poster Presentation

Stanley 2026.03.19 No Comments

AACR 2026 selected OP820, a mucin-binding microbiome oncology candidate identified using ORGANOPlus’ villus-mimicking organ-on-a-chip platform, demonstrating translational efficacy across both in vitro and in vivo models.

ORGANOPlus established its first European entity in Copenhagen

Stanley 2026.03.05 No Comments

By establishing its first European entity in Copenhagen, South Korean ORGANOPlus embeds its validation platform within Medicon Valley’s strong ecosystem. And it’s doing so with assistance from Copenhagen Capacity. Go…

Category: In the News